Daily hydroxyl radical scavenging capacity of mammals

Ienaga, Kazuharu; Park, Chan Hum; Yokozawa, Takako

doi:10.5582/ddt.8.71

Cited by 4 publications

(2 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolites related to methylamine metabolism, such as dimethylglycine and trime-thylamine N-oxide, are systemic breakdown products of choline [5] that, due to their osmoregulatory properties, may be linked to a hyperosmotic effect of glucose or indicate renal papillary dysfunction when found in high concentrations [26]. In our study, decreased urinary levels of creatinine and its metabolite methylguanidine [27] were also observed, which could be related to alterations of glomerular filtration rate (GFR) in T2D with a possible decrease of muscle mass [28], although our participants were free of nephropathy. However, in a recent report, lower creatinine excretion rates were associated with all-cause mortality in diabetes patients and in nephropathy [28].…”

Section: Discussionsupporting

confidence: 49%

Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants

Urpí-Sardà

Almanza-Aguilera

Llorach

et al. 2019

Diabetes & Metabolism

View full text Add to dashboard Cite

The multi-metabolite signature of T2D highlights the altered metabolic fingerprint associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified in this patient population could be related to higher risk of long-term cardiovascular events and therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic complexity and interindividual variation in T2D towards the development of stratified precision nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639.

show abstract

Section: Discussionsupporting

confidence: 49%

Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants

Urpí-Sardà

Almanza-Aguilera

Llorach

et al. 2019

Diabetes & Metabolism

View full text Add to dashboard Cite

show abstract

“…For example, • OH is short-lived (biological half-life (t 1/2 ): 10 −9 s), but most damaging free radicals in our body. It is evident to cause deleterious biological effects including lipid peroxidation in our body (38). An interaction of Cu 2+ or Fe 2+ and hydrogen peroxide A mismatch between ROS scavenging and generation promotes oxidative stress and inflammation in our body (41).…”

Section: Discussionmentioning

confidence: 99%

Agathisflavone: Botanical sources, therapeutic promises, and molecular docking study

et al. 2019

View full text Add to dashboard Cite

In this article, we have summarized the biological sources and pharmacological activities of agathisflavone along with molecular docking studies to correlate the interaction of this biflavonoid and biomacromolecules involving in its biological effects observed in database‐oriented scientific reports. For this, an up‐to‐date (from 1991 to October 2018) search was done on the databases such as PubMed, Science Direct, Web of Science, Scopus, The American Chemical Society, http://clinicaltrials.gov, and Google Scholar databases. The findings suggest that agathisflavone possesses antioxidant, anti‐inflammatory, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective activities. An in silico study of agathisflavone against 17 essential proteins/enzymes revealed that inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)‐2 are the most efficient enzymes for the interaction and binding of this biflavonoid for its anti‐inflammatory activity. In conclusion, agathisflavone may be one of the promising plant‐derived lead compounds in the treatment of oxidative stress, inflammatory diseases, microbial infection, hepatic and neurological diseases and disorders, and cancer. © 2019 IUBMB Life, 71(9):1192–1200, 2019

show abstract

Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury

Mercantepe

Topçu

et al. 2018

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Despite the enormous advances made in the field of oncology, no solution to the side effect of nephrotoxicity caused by cisplatin used as an antineoplastic agent for approximately 40 years has yet been discovered. This study investigated the effects of cisplatin on the kidney, the damage mechanism involved, and the potential capacity of agents such as amifostine, curcumin, and melatonin to elicit a future therapeutic protocol in cisplatin-induced nephrotoxicity at the ultrastructural and molecular levels. Our study consisted of five groups: control (saline solution only; group 1), cisplatin (cisplatin only; group 2), cisplatin + amifostine (group 3), cisplatin + curcumin (group 4), and cisplatin + melatonin (group 5). Rats in all groups except the control group were administered a single intraperitoneal dose of 7.5 mg/kg cisplatin. All animals were sacrificed under anesthesia on the sixth day after cisplatin administration. Cisplatin increased serum urea and serum creatinine levels and caused an increase in tubular necrosis scores (TNS), HPS, NF-κB/p65, 8-OHdG, and caspase-3 expressions (p < 0.05). Additionally, we observed basal membrane thickening in glomerules, intense electron deposition in the subendothelial region, and atypical folds in podocyte pedicels. Amifostine, curcumin, and melatonin reduced the increases in serum urea and serum creatinine levels following cisplatin administration and reduced the levels of TNS, HPS, NF-κB/p65, 8-OHdG, and caspase-3 expressions (p < 0.05). ROS-scavenging antioxidants may be a promising means of preventing acute kidney disease in patients using cisplatin in the treatment of malignant tumors.

show abstract

Daily hydroxyl radical scavenging capacity of mammals

Cited by 4 publications

References 18 publications

Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants

Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants

Agathisflavone: Botanical sources, therapeutic promises, and molecular docking study

Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury

Contact Info

Product

Resources

About